Related Experiment Video
Updated: Jun 8, 2026
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Examining the safety profile of angiogenesis inhibitors: implications for clinical practice
1Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany. Dr.Martin.Reck@web.de
Abstract:
Dysregulation of angiogenesis in solid tumors enables tumor growth and metastasis. Receptors that mediate angiogenesis, and their ligands, have been identified; among these, vascular endothelial growth factor (VEGF) and its receptor tyrosine kinase play a central role. In non-small cell lung cancer (NSCLC), clinical benefit has been shown with bevacizumab, which blocks VEGF binding to its receptors. In addition, small-molecule tyrosine kinase inhibitors are currently in clinical practice or development in several indications. The potential clinical benefit of antiangiogenic agents is accompanied by the need to understand their safety profiles, seek suitable combination regimens and identify patients able to tolerate one treatment over another. This is particularly relevant in cancers for which patients often present with advanced disease and suffer co-morbidities, requiring an agent that is both efficacious and well tolerated over long-term continuous treatment. Using literature from peer-reviewed journals, this review considers different antiangiogenic agents and their safety profiles, focusing on the potential impact of these data on the treatment of patients with NSCLC.
Insights
Antiangiogenic agents targeting vascular endothelial growth factor (VEGF) show promise for non-small cell lung cancer (NSCLC). This review examines their safety profiles for long-term use in patients with advanced disease and co-morbidities.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Dysregulated angiogenesis is crucial for solid tumor growth and metastasis.
- Vascular Endothelial Growth Factor (VEGF) and its receptor tyrosine kinase are central mediators of angiogenesis.
- Antiangiogenic therapies, including bevacizumab and tyrosine kinase inhibitors, are established or in development for various cancers.
Purpose of the Study:
- To review different antiangiogenic agents and their safety profiles.
- To focus on the impact of safety data on non-small cell lung cancer (NSCLC) treatment.
- To identify suitable combination regimens and patient selection criteria for antiangiogenic therapy.
Main Methods:
- Literature review of peer-reviewed journals.
- Analysis of safety profiles of antiangiogenic agents.
- Evaluation of clinical benefit and tolerability data.
Main Results:
- Antiangiogenic agents offer clinical benefit in NSCLC, exemplified by bevacizumab.
- Understanding safety profiles is critical for long-term treatment, especially in patients with advanced disease and co-morbidities.
- Further research is needed to optimize combination regimens and patient selection.
Conclusions:
- Antiangiogenic therapy holds significant potential for NSCLC treatment.
- Careful consideration of safety and tolerability is essential for continuous, long-term therapy.
- Personalized treatment strategies are needed to maximize efficacy and minimize toxicity in NSCLC patients.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...